[HTML] nejm.org

[HTML][HTML] Sotagliflozin in patients with diabetes and chronic kidney disease

DL Bhatt, M Szarek, B Pitt, CP Cannon… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …
被引用次数：938 相关文章

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

M Szarek, B Pitt, CP Cannon, LA Leiter… - … England Journal of …, 2021 - repository.ukim.mk
BACKGROUND The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such
as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Sotagliflozin in patients with diabetes and chronic kidney disease

DL Bhatt, M Szarek, B Pitt, CP Cannon… - … England Journal of …, 2021 - research.aston.ac.uk
BACKGROUND: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such
as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

LB Deepak, PC Christopher, AL Lawrence… - NEW ENGLAND …, 2021 - iris.unicz.it
Background: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Sotagliflozin in patients with diabetes and chronic kidney disease

DL Bhatt, M Szarek, B Pitt… - New England …, 2021 - utsouthwestern.elsevierpure.com
BACKGROUND The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

DL Bhatt, M Szarek, B Pitt… - The New England …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.

DL Bhatt, M Szarek, B Pitt, CP Cannon… - The New England …, 2020 - europepmc.org
Background The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

DL Bhatt, M Szarek, B Pitt, CP Cannon… - New England Journal …, 2021 - cir.nii.ac.jp
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

DL Bhatt, M Szarek, B Pitt, CP Cannon… - … England Journal of …, 2021 - publicum.umed.lodz.pl
BACKGROUND The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such
as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Sotagliflozin in patients with diabetes and chronic kidney disease

DL Bhatt, M Szarek, B Pitt… - … England Journal of …, 2021 - publications.aston.ac.uk
BACKGROUND: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such
as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …